A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia.

Publisher Website
Google Scholar
Abstract
While the atypical antipsychotics should ultimately reduce the prevalence of tardive dyskinesia, it is likely to remain a significant clinical problem for a long time to come. No strategy has clearly emerged as the treatment of choice for tardive dyskinesia. Atypical antipsychotics have reduced propensities for producing acute extrapyramidal symptoms (EPS) and possibly tardive dyskinesia and may be effective in treating patients with established tardive dyskinesia.

This publication has 0 references indexed in Scilit: